By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.
The Informed is Root to Rx's deep-dive science track, for when you want to check the work yourself instead of taking the plain-language version on faith.
If you want the character story and how to get to a place where you can have a conversation with someone about a health claim, read The Root Room (the testing bench, where Jay’s bottles get measured). If you want the plain how-to for assessing a health claim, read Plain Talk. This is the evidence underneath, for when you want to check every detail yourself.
From Issue 015
Issue 015 traced how a drug’s risk profile is generated and verified. This issue examines products that produce drug-like effects while bypassing that process entirely, and why natural is a statement about origin, not pharmacology.
Red yeast rice and monacolin K
Red yeast rice is produced by fermenting rice with a mold that generates monacolins. The principal active, monacolin K, is structurally identical to lovastatin, a prescription HMG-CoA reductase inhibitor. The consequence is direct: a product sold as a supplement can deliver a pharmacologically active statin dose. Content varies substantially between products. When 28 mainstream brands were analyzed, monacolin K ranged more than 60-fold across the products that contained it, and more than 120-fold once each label’s recommended daily serving was followed. None of the labels stated the amount. Some products have also been found to contain citrinin, a nephrotoxic mycotoxin. U.S. regulators have treated products with meaningful monacolin K content as unapproved drugs. [2][3][4]
Lovastatin is the same molecule in both bottles.
Berberine and AMPK
Berberine’s primary metabolic effect appears to run through activation of AMP-activated protein kinase (AMPK), a pathway more analogous to metformin than to incretin therapies. It is not a GLP-1 receptor agonist and does not share Ozempic’s mechanism. A 2025 systematic review and meta-analysis of randomized placebo-controlled trials found modest improvements in several metabolic-syndrome markers (LDL cholesterol, total cholesterol, triglycerides, fasting glucose, waist circumference, BMI) with a safety profile comparable to placebo, an evidence base far smaller and shorter than that behind approved GLP-1 drugs. Berberine may also affect drug-metabolizing enzymes, creating interaction potential, and its glucose effects can be additive with metformin. [1]
The pharmacological principle
A compound with a genuine mechanism has a genuine dose-response curve and genuine interactions. There is no pharmacological category called natural that exempts a molecule from these properties. The plants and fungi that supplements come from contain bioactive compounds precisely because those compounds do something, which is the same reason they carry risk.
What safe actually means
Safe is not the absence of risk. It is characterized risk. A safe medicine is one whose dose, effects, interactions, and failure modes have been measured and written down, and whose manufacturing is controlled so that each unit matches the label. Even then, response varies between individuals because of genetics, kidney and liver function, age, and concurrent medications. That interindividual variability is precisely why dose standardization, labeling, and monitoring exist: they are the tools that keep a known-but-variable risk inside a known range. A supplement that delivers a drug’s effect without any of that is not safer than the drug. It is the same class of risk with the measurements removed, plus one more unmeasured variable: what is actually in this particular bottle.
The regulatory inversion
The prescription version of these effects is dose-standardized, tested, labeled, and monitored. The supplement version is none of these, yet is frequently perceived as the safer choice. The perception is inverted relative to the evidence: the product with less oversight is trusted more, specifically because it is marketed as natural. There is a whole discipline that exists to build that oversight, the schedule of assessments, the source documentation, the causality judgments made at trial sites. Strip it away and you do not get a safer product. You get the same molecule with the assurances removed.
A note from my clinical trial project management desk, and former clinical trial coordinator experience
In clinical research, the entire apparatus exists to answer one question about any effect a product has: did the product cause it, at what dose, and how do we know. A supplement that borrows a drug’s effect borrows none of that machinery. That’s not a small omission. It’s the whole difference between a measured intervention and a hope in a bottle.
Here’s what that machinery looks like in real life. A participant on a cardiology study drug was driving across several states to see family. The driver in front slammed the brakes to avoid a deer. The study participant rear ended that car and badly broke a leg, along with other injuries from the crash. All of it was reported as a serious adverse event at the trial site, because it happened after informed consent, while the person was on study.
I say this because it happened to me. I personally requested those hospital records from a state ten states away from where I was working, filled out the forms, and got my investigator to assess whether the event could be related to the study drug, all inside the mandatory 24-hour window from when we became aware.
A broken leg from a car accident would never make it onto the drug commercial for that cholesterol drug, because the investigator could reasonably attribute it to the crash, not the medicine. But if the same participant had reported something like lightheadedness, something that could plausibly trace back to the drug, then the investigator and the medical safety teams would weigh it carefully, keep it on the record, and it would count toward the drug’s known risk profile. That is the line the entire system is built to draw: separating what the product did from everything else happening in a person’s life.
A supplement borrows the drug’s effect and skips every part of that line-drawing. Nobody requests the records. Nobody assesses causality. Nobody files anything within 24 hours, because there is no trial, no investigator, and no safety team watching. The effect is real. The accounting is gone. That’s not to say the supplement can’t or won’t work. It just hasn’t been through the same testing or the same manufacturing quality control. Similar to getting beef jerky at the grocery store, versus the guy on the side of the road heading into the country selling it from his truck. Could be the best beef jerky in the world, but it’s Russian Roulette.
For the Record
If you work in clinical research or pharmacy: the monacolin K case is a clean teaching example of why source and standardization matter. The same molecule under two regulatory regimes carries very different assurances of dose and purity.
If you are a patient or advocate: treat any supplement that claims a drug-like effect as pharmacologically active. Disclose it, and ask your pharmacist about overlap with your prescriptions. Free personal Conmed log.
If you are a general reader: natural describes where a substance comes from. It says nothing about dose, potency, interactions, or safety. Those have to be measured, and for most supplements, they were not required to be.
Read the Rest of Issue 016
The Root Room, The Room That Actually Checks: Jay’s bottles go to an independent lab and get measured.
Plain Talk, The Supplement That Wants to Be a Drug: the plain rule and the Toolkit questions.
The Verdict, Friday: the two claims go on trial and get their labels.
References
[1] Liu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology. 2025;16:1572197.
[2] Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. European Journal of Preventive Cardiology. 2017;24(13):1431 to 1434.
[3] National Center for Complementary and Integrative Health (NIH). Red Yeast Rice. nccih.nih.gov/health/red-yeast-rice
[4] U.S. FDA determination that red yeast rice products containing more than trace monacolin K are unapproved new drugs (Pharmanex v. Shalala, upheld 2001).
Refer a friend: if this was worth your time, the best thanks is a referral. Series 1 collector cards are the reward. [Referral: insert your Beehiiv Referral Program block, or set the button link to your referral URL.]
Try it yourself: apply the toolkit above to a claim of your own. The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type. Got Skepticism? runs any claim through the same five-move toolkit used in this issue. Stay in the Room shows you how to disagree without a fight. Both play in your browser at openlabelmedia.com, and I would love to see your results on social.
For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.
Instagram: instagram.com/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | Subscribe: RootToRx.com
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States